Pfizer Inc. and MiMedx Group, Inc.: SG&A Spending Patterns Compared

A Tale of Two Companies: SG&A Spending Trends

In the world of pharmaceuticals and biotechnology, understanding spending patterns can reveal much about a company's strategic priorities. Over the past decade, Pfizer Inc. and MiMedx Group, Inc. have shown contrasting approaches in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This consistency reflects Pfizer's robust market position and strategic investments in maintaining its global presence.

Conversely, MiMedx Group, Inc. has seen a more dynamic trend, with SG&A expenses growing by approximately 133% from 2014 to 2018, before stabilizing. This growth phase indicates MiMedx's aggressive expansion and market penetration efforts. By 2023, MiMedx's SG&A expenses reached over $200 million, highlighting its commitment to scaling operations. These spending patterns underscore the distinct paths these companies have taken in navigating the competitive landscape.